Fisher & Paykel Healthcare Corporation Limited (ASX:FPH)
Share Pricing & News Healthcare

AUD 21.8

-0.23 (1.044%)
(As on 2022-12-08 20:56:02 AEDT)
Previous Close Open Close*
22.03 22.1 21.8
Market Cap Dividend Yield (Annualized)
AUD 12.591B 1.59%

Day Range
21.8L 22.26 H
16.11L 31.35 H

Chart Price & Information

Last Trade 21.8
Change% -1.0440
52 W H/L 31.350/16.110
NPAT After Abnormal Items 376.9M
Equity 1.68B
ROE% 22.44%
Total Liabilities 427.3M
Total Revenue 1.682B
Cash and Cash Equivalents 89.9M

Stock Information

Share price 21.8
Market Cap 12.591B
Price/Gross Cash Flow 31.21
Dividend Yield Excluding Special 1.59%
Ending Shares 577.406M
52-Week Range 31.350-16.110
Gross DPS (AUD) 0.3882
Gross Dividend Yield (Annualized) 1.59%
Earnings Yield 1.800
Net Tangible Asset (NTA) 2.76
P/E ratio 55.556
Sector P/E --
EPS 65.00
Net Profit Margin (%) 22.95%
Gross Cash Flows Per Share 0.78
Net Gearing 0.86%
Sales Per Share 2.83
Book Value Per Share 2.91

Similar Companies

Related Articles

About Company

Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) is a health care equipment and services company which was listed on the Australian Securities Exchange (ASX) on 21 November 2001, under the ticker code FPH. Headquartered in East Tamaki, the company designs, manufactures and markets systems and products which are used in chronic and acute respiratory surgery, treatment, and care of obstructive sleep apnea. The company is also listed on the New Zealand Stock Exchange. The medical technologies and devices offered by the company help clinicians deliver patient care. The devices assist the patients in transitioning into less-acute care settings, avoiding serious conditions and recovering quickly. The therapies and products offered by the group help the patients to be treated at their preferred place, like a home rather than a hospital. The company marked its beginning in 1969 with the development of the first prototype respiratory humidifier. Initially, the company was engaged in producing products for invasive ventilation; later, it expanded its offerings to other clinical applications that includes nasal high flow therapy. Products for non-invasive ventilation and treatment of obstructive sleep apnea. The product portfolio was also expanded to address the need of children and infants. 

Corporate Information

15 Maurice Paykel Place, East Tamaki, AUSTRALIA,

Phone:+64 9 574 0100



Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2023-11-28 2023
Report (Annual) 2023-05-24 2023
Report (Prelim) 2023-05-24 2023
Div Pay Date 2022-12-21 2022
Books Close 2022-12-09 2022